-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, GI/LiPD9zaCrQVwyQgM/YJ84Im8Y31IWhadhHBajMg7V9BvAZclbm8gw9hayAArG UdEr+TRYxdhXB9yltrbR9Q== 0001127602-10-006329.txt : 20100225 0001127602-10-006329.hdr.sgml : 20100225 20100225170928 ACCESSION NUMBER: 0001127602-10-006329 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20100223 FILED AS OF DATE: 20100225 DATE AS OF CHANGE: 20100225 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MacLean Michael F CENTRAL INDEX KEY: 0001383731 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19311 FILM NUMBER: 10634525 MAIL ADDRESS: STREET 1: 14 CAMBRIDGE CENTER CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOGEN IDEC INC. CENTRAL INDEX KEY: 0000875045 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330112644 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 14 CAMBRIDGE CENTER CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 6176792000 MAIL ADDRESS: STREET 1: 14 CAMBRIDGE CENTER CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: BIOGEN IDEC INC DATE OF NAME CHANGE: 20031112 FORMER COMPANY: FORMER CONFORMED NAME: IDEC PHARMACEUTICALS CORP / DE DATE OF NAME CHANGE: 19970530 4 1 form4.xml PRIMARY DOCUMENT X0303 4 2010-02-23 0000875045 BIOGEN IDEC INC. BIIB 0001383731 MacLean Michael F 14 CAMBRIDGE CENTER CAMBRIDGE MA 02142 1 SVP, Chief Accounting Officer Common Stock 2010-02-24 4 A 0 3990 0 A 25248.9467 D Common Stock 2010-02-24 4 F 0 423 55.29 D 24825.9467 D Common Stock 2010-02-24 4 F 0 427 55.29 D 24398.9467 D Restricted Stock Unit 0 2010-02-23 4 A 0 6114 0 A 2014-02-23 Common Stock 6114 6114 D The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 150% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest on each of the first four anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average 60 calendar-day closing stock price ending on the vesting date divided by the average 60 calendar-day closing stock price on the grant date]). There is no conversion or exercise price for this stock unit. Aras Lapinskas, Attorney in Fact for Michael F. MacLean 2010-02-25 -----END PRIVACY-ENHANCED MESSAGE-----